Global Erlotinib Hydrochloride Market Study 2015-2025, by Segment (25mg, 100mg, 150mg), by Market (Non-small Cell Lung Cancer, Pancreatic Cancer100mg), by Company (Roche, Cipla, Mylan)
ReportPage
Report ID
16370
Published Date
21-Sep
No of Report Page
87
Report Category
Editor's Rating
US $3,600.00
US $3,600.00
US $1,800.00

  • Report Details 
    Snapshot
    
Erlotinib Hydrochloride is an anticancer drug from protein kinase inhibitors pharmacological group. This medication is used for the treatment of non-small cell lung cancer (NSCLC), locally advanced, unresectable or metastatic pancreatic cancer, and several other types of cancer. It is usually given after other cancer medicines have been tried without success. Erlotinib acts on the epiderm
    More...
  • Table Of Content 
    Table of Content
    
1 Industry Overview
    
    1.1 Erlotinib Hydrochloride Industry
    
        1.1.1 Overview
    
        1.1.2 Products of Major Companies
    
    1.2 Market Segment
    
        1.2.1 Industry Chain
    
        1.2.2 Consumer Distribution
    
    1.3 Price & Cost Overview
    
2 Erlotinib Hydrochloride Market by Type
    
    2.1 By Type
    
       2.1.1 25mg
    
       2.1.2 100mg
    
       2.1.3 150mg
    
    2.2 Market Size by Typ
    More...
  • Inquiry Before Buying
    Inquiry Before Buying -
  • Request Sample
    Request For Sample
portalmarketdeskus
 
Survey No. 3/1,4/1/3 Rajwade Commercial Complex Office No. 8, Phase 2 Behind SBI Bank, Pune - Bengaluru Hwy, Ambegaon BK, Pune, Maharashtra 411046
Navigation : -
Connect with Us : -
Secured Payment Options : -